Nutrition Can Modify Gut-Brain Axis and Medication Induced Metabolic Disorders in Autism Spectrum Disorder- A Hypothesis

Article Sidebar

PDF
Published: Sep 27, 2022
DOI: https://doi.org/10.47191/ijpbms/v2-i9-07

Main Article Content

Kimia Moiniafshari
Food and Health group, Department of Land, Environment, Agriculture and Forestry, University of Padova, Padova, Italy
Farshad kalantari
Department of physical education and sport sciences, Islamic Azad University, East Tehran Branch, Tehran, Iran
Hafez Behzadi Nezhad
Department of physical education and sport sciences, University of Tehran, Tehran, Iran

Abstract

Autism Spectrum Disorder (ASD), is a neurodevelopmental disorder which is accompanied by several health-related challenges. Nutritional and gastrointestinal problems are common among individuals with ASD. Gut microbiota imbalance may be a reason of nutritional problems including food selectivity and restricted dietary intake. Nutritional problems and gut microbiota imbalance can increase behavioral symptoms which may increase the possibility and necessity for medication. It has been suggested that some medications, may increase the risk of metabolic impairments including glucose homeostasis abnormality, insulin resistance and/or diabetes. In this manuscript, we hypothesized that gut microbiota improvement via probiotic consumption, may improve GI problems and modify behavioral symptoms, which seems to manage medication prescription necessity.

Article Details

How to Cite
Moiniafshari, K., kalantari, F., & Behzadi Nezhad, H. . (2022). Nutrition Can Modify Gut-Brain Axis and Medication Induced Metabolic Disorders in Autism Spectrum Disorder- A Hypothesis. International Journal of Pharmaceutical and Bio Medical Science, 2(9), 373–375. https://doi.org/10.47191/ijpbms/v2-i9-07
Issue
Vol. 2 No. 9 (2022): Volume 02 Issue 09 September 2022
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

I. Lu, J., Wang, Z., Liang, Y., & Yao, P. (2022). Rethinking autism: The impact of maternal risk factors on autism development. American Journal of Translational Research, 14(2), 1136.

II. Cortese, S., Gabellone, A., Marzulli, L., Iturmendi-Sabater, I., de La Chica-Duarte, D., Piqué, I. M., ... & Arrondo, G. (2022). Association between autism spectrum disorder and diabetes: systematic review and meta-analysis. Neuroscience & Biobehavioral Reviews, 104592.

III. Katz, J., Reichenberg, A., & Kolevzon, A. (2021). Prenatal and perinatal metabolic risk factors for autism: A review and integration of findings from population-based studies. Current opinion in psychiatry, 34(2), 94-104.

IV. Dhaliwal, K. K., Avedzi, H. M., Richard, C., Zwaigenbaum, L., & Haqq, A. M. (2022). Brief Report: Plasma Leptin and Mealtime Feeding Behaviors Among Children with Autism Spectrum Disorder: A Pilot Study. Journal of Autism and Developmental Disorders, 1-8.

V. Sukasem C, Vanwong N, Srisawasdi P, et al. Pharmacogenetics of risperidone-induced insulin resistance in children and adolescents with autism spectrum disorder. Basic Clin Pharmacol Toxicol2018;123:42-50.

VI. Hervas, A., Serra-LLovich, A., Rueda, I., Targa, I., Guijarro, S., Bigorra, A., ... & Arranz, M. J. (2021). Pharmacogenetic influences on the response to pharmacological treatment in autism spectrum disorders. Journal of Translational Genetics and Genomics, 5(3), 278-287.

VII. Turpin, P. L., Ahrens, A. P., Russell, J. T., Kindgren, E., Berryman, M. A., Ilonen, J., ... & Ludvigsson, J. (2021). Adolescent autism and autoimmune diagnoses linked to infant gut bacteria whose prevalence is associated with at-risk genetics and/or diet. medRxiv.

VIII. Zhang, Q., Zou, R., Guo, M., Duan, M., Li, Q., & Zheng, H. (2021). Comparison of gut microbiota between adults with autism spectrum disorder and obese adults. PeerJ, 9, e10946.

IX. Biswas, M., Vanwong, N., & Sukasem, C. (2022). Pharmacogenomics in clinical practice to prevent risperidone-induced hyperprolactinemia in autism spectrum disorder. Pharmacogenomics, (0).

X. Patel, D. (2022). Dietary Approaches to the Treatment of Autism Spectrum Disorders.

XI. Kong, X. J., Liu, J., Liu, K., Koh, M., Sherman, H., Liu, S., ... & Fong, M. (2021). Probiotic and Oxytocin Combination Therapy in Patients with Autism Spectrum Disorder: A Randomized, Double-Blinded, Placebo-Controlled Pilot Trial. Nutrients 2021, 13, 1552.

XII. Kerry, R. G., Das, G., Golla, U., del Pilar Rodriguez-Torres, M., Shin, H. S., & Patra, J. K. (2022). Engineered probiotic and prebiotic nutraceutical supplementations in combating non-communicable disorders: A review. Current Pharmaceutical Biotechnology, 23(1), 72-97.

XIII. Nettleton, J. E., Klancic, T., Schick, A., Choo, A. C., Cheng, N., Shearer, J., ... & Reimer, R. A. (2021). Prebiotic, Probiotic, and Synbiotic Consumption Alter Behavioral Variables and Intestinal Permeability and Microbiota in BTBR Mice. Microorganisms, 9(9), 1833.

XIV. Sunand, K., Mohan, G. K., & Bakshi, V. (2021). Synergetic Potential of Combination Probiotic Complex with Phytopharmaceuticals in Valproic Acid Induced Autism: Prenatal Model. INTERNATIONAL JOURNAL OF APPLIED PHARMACEUTICAL SCIENCES AND RESEARCH, 6(03), 33-43.